KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Times Interest Earned (2020 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Times Interest Earned for 7 consecutive years, with $3.88 as the latest value for Q1 2026.

  • For Q1 2026, Times Interest Earned rose 1150.63% year-over-year to $3.88; the TTM value through Mar 2026 reached $3.43, up 590.18%, while the annual FY2025 figure was $1.99, 259.23% up from the prior year.
  • Times Interest Earned hit $3.88 in Q1 2026 for Alnylam Pharmaceuticals, up from $2.01 in the prior quarter.
  • Across five years, Times Interest Earned topped out at $8.29 in Q3 2025 and bottomed at -$7.65 in Q2 2023.
  • Average Times Interest Earned over 5 years is -$1.22, with a median of -$2.24 recorded in 2024.
  • Year-over-year, Times Interest Earned plummeted 132.32% in 2024 and then soared 1150.63% in 2026.
  • Alnylam Pharmaceuticals' Times Interest Earned stood at -$6.31 in 2022, then surged by 41.09% to -$3.71 in 2023, then rose by 27.35% to -$2.7 in 2024, then surged by 174.64% to $2.01 in 2025, then soared by 92.51% to $3.88 in 2026.
  • According to Business Quant data, Times Interest Earned over the past three periods came in at $3.88, $2.01, and $8.29 for Q1 2026, Q4 2025, and Q3 2025 respectively.